Turning Point Therapeutics Dirección
Dirección controles de criterios 1/4
El CEO de Turning Point Therapeutics' es Athena Countouriotis , nombrado en Sep 2018, tiene una permanencia de 3.92 años. compensación anual total es $16.94M, compuesta por 3.8% salario y 96.2% primas, incluidas acciones y opciones de la empresa. posee directamente un 0.22% de las acciones de la empresa, por valor de $8.39M. La antigüedad media del equipo directivo y de la junta directiva es de 2.3 años y 2 años, respectivamente.
Información clave
Athena Countouriotis
Chief Executive Officer (CEO)
US$16.9m
Compensación total
| Porcentaje del salario del CEO | 3.8% |
| Permanencia del CEO | 3.9yrs |
| Participación del CEO | 0.2% |
| Permanencia media de la dirección | 2.3yrs |
| Promedio de permanencia en la Junta Directiva | 2yrs |
Actualizaciones recientes de la dirección
Recent updates
Bristol Myers U.S., German antitrust filings for Turning Point expected very soon - report
Jul 21We Think Turning Point Therapeutics (NASDAQ:TPTX) Can Afford To Drive Business Growth
Mar 23
Companies Like Turning Point Therapeutics (NASDAQ:TPTX) Are In A Position To Invest In Growth
Dec 06The Take On Turning Point Therapeutics
Dec 03Industry Analysts Just Made A Sizeable Upgrade To Their Turning Point Therapeutics, Inc. (NASDAQ:TPTX) Revenue Forecasts
Aug 15Turning Point Therapeutics (NASDAQ:TPTX) Is In A Strong Position To Grow Its Business
Aug 04Turning Point Therapeutics gets FDA orphan drug status for TPX-0022 in gastric cancer
Jun 17Turning Point Therapeutics, Inc. (NASDAQ:TPTX) Just Reported First-Quarter Earnings: Have Analysts Changed Their Mind On The Stock?
May 08Have Insiders Been Selling Turning Point Therapeutics, Inc. (NASDAQ:TPTX) Shares This Year?
Feb 26Turning Point Therapeutics' repotrectinib shows promising results in lung cancer study
Jan 29Analysts' Revenue Estimates For Turning Point Therapeutics, Inc. (NASDAQ:TPTX) Are Surging Higher
Jan 22
We're Not Worried About Turning Point Therapeutics' (NASDAQ:TPTX) Cash Burn
Jan 13Turning Point Therapeutics: An Emerging Growth Story In TKI-Resistant Cancers
Dec 28Is Turning Point Therapeutics, Inc. (NASDAQ:TPTX) Trading At A 48% Discount?
Dec 15Turning Point Therapeutics' lead candidate nabs accelerated review for lung cancer
Dec 08Turning Point Therapeutics EPS beats by $0.12, beats on revenue
Nov 12Análisis de compensación del CEO
| Fecha | Compensación total | Salario | Ingresos de la empresa |
|---|---|---|---|
| Jun 30 2022 | n/a | n/a | -US$342m |
| Mar 31 2022 | n/a | n/a | -US$275m |
| Dec 31 2021 | US$17m | US$651k | -US$237m |
| Sep 30 2021 | n/a | n/a | -US$205m |
| Jun 30 2021 | n/a | n/a | -US$157m |
| Mar 31 2021 | n/a | n/a | -US$132m |
| Dec 31 2020 | US$15m | US$580k | -US$157m |
| Sep 30 2020 | n/a | n/a | -US$131m |
| Jun 30 2020 | n/a | n/a | -US$134m |
| Mar 31 2020 | n/a | n/a | -US$119m |
| Dec 31 2019 | US$3m | US$544k | -US$72m |
| Sep 30 2019 | n/a | n/a | -US$60m |
| Jun 30 2019 | n/a | n/a | -US$46m |
| Mar 31 2019 | n/a | n/a | -US$34m |
| Dec 31 2018 | US$9m | US$329k | -US$25m |
Compensación vs. Mercado: La compensación total de Athena($USD16.94M) está por encima de la media de empresas de tamaño similar en el mercado US ($USD6.66M).
Compensación vs. Ingresos: La compensación de Athena ha aumentado mientras la empresa no es rentable.
CEO
Athena Countouriotis (50 yo)
3.9yrs
Permanencia
US$16,940,858
Compensación
Dr. Athena Maria Countouriotis, M.D. is Chief Executive Officer and Director at Turning Point Therapeutics, Inc. since September 2018. She has been Independent Director of Passage Bio, Inc since February 2...
Equipo directivo
| Nombre | Posición | Permanencia | Compensación | Propiedad |
|---|---|---|---|---|
| President | 3.9yrs | US$16.94m | 0.22% $ 8.4m | |
| Executive VP & CFO | 1.1yrs | US$4.58m | 0.057% $ 2.2m | |
| Executive VP & Chief Medical Officer | 2.7yrs | US$5.61m | 0.082% $ 3.1m | |
| Senior VP & Chief Information Officer | no data | sin datos | sin datos | |
| Senior VP of Chemistry & Interim Chief Scientific Officer | no data | sin datos | sin datos | |
| Senior Vice President of Investor Relations & Corporate Communications | less than a year | sin datos | sin datos | |
| Senior VP & Chief Compliance Officer | no data | sin datos | sin datos | |
| Senior VP | less than a year | sin datos | sin datos | |
| Senior Vice President of Human Resources | 2.1yrs | sin datos | sin datos | |
| Senior Vice President of Pre-Clinical Development | no data | sin datos | sin datos | |
| Senior Vice President of Clinical Development | 3.6yrs | sin datos | sin datos | |
| Senior VP | 2.6yrs | sin datos | sin datos |
2.3yrs
Permanencia media
52yo
Promedio de edad
Equipo directivo experimentado: El equipo directivo de TPTX se considera experimentado (2.3 años antigüedad media).
Miembros de la Junta
| Nombre | Posición | Permanencia | Compensación | Propiedad |
|---|---|---|---|---|
| President | 3.9yrs | US$16.94m | 0.22% $ 8.4m | |
| Chairman of Scientific Advisory Board | 2yrs | sin datos | sin datos | |
| Independent Director | 3.3yrs | US$424.79k | 0% $ 0 | |
| Independent Director | 3.1yrs | US$415.29k | 0% $ 0 | |
| Member of Scientific Advisory Board | 2yrs | sin datos | 0% $ 0 | |
| Independent Director | 2.6yrs | US$422.74k | 0% $ 0 | |
| Independent Non-Executive Director | 5.3yrs | US$414.41k | 0% $ 0 | |
| Independent Chairman of the Board | 1.3yrs | US$861.18k | 0.0040% $ 151.9k | |
| Independent Director | 1.4yrs | US$1.00m | sin datos | |
| Member of Scientific Advisory Board | no data | sin datos | sin datos | |
| Member of the Scientific Advisory Board | 2yrs | sin datos | sin datos | |
| Member of the Scientific Advisory Board | 2yrs | sin datos | sin datos |
2.0yrs
Permanencia media
55.5yo
Promedio de edad
Junta con experiencia: La junta directiva de TPTX no se considera experimentada (2 años de permanencia promedio), lo que sugiere una nueva junta directiva.